ReviewHuman molecular genetics2017
Genetics of age-related macular degeneration (AMD).
Review in Human molecular genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 88 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- Pooled it
- The Effect of Dietary Supplementations on Delaying the Progression of Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis.Nutrients · 2022Pooled it
- Genetic evidence and cross-species functional characterization implicateProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Oxidative stress promotes the progression of age-related macular degeneration by up-regulating Spp1 to activate the JAK/STAT signaling pathway.Scientific reports · 2026Article
- Carotenoid Status and Psychological Impact of Presymptomatic Macular Degeneration Genetic Risk Assessment: The MAGENTA Randomized Trial.Ophthalmology science · 2026Article
- Integrating genetics, age and imaging to predict treatment outcomes in neovascular age-related macular degeneration: a proof-of-concept study.Scientific reports · 2026Article
- The MTRNR2L gene family and age-related macular degeneration.Frontiers in immunology · 2026Review
- Article
- 'EarlyAMDRate': A grading instrument for OCT-based assessment of early lesions caused by age-related macular degeneration.Acta ophthalmologica · 2025Article
- Article
- Genetic Associations of Rod- and Cone-Mediated Vision in Aging and Age-Related Macular Degeneration.Investigative ophthalmology & visual science · 2025Article
- Polygenic Risk Score Impact on Visual Function in Older Individuals with Healthy Macula: The Northern Ireland Sensory Ageing Study.Eye (London, England) · 2025Article
- Computer modeling of bevacizumab drug distribution after intravitreal injection in rabbit and human eyes.Journal of pharmaceutical sciences · 2025Article
- Extracting full information from OCT scans-signs of early age-related macular degeneration within inner retinal layers by local neighbourhood statistics. Part I: Methodology.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025Article
- Longitudinal Choriocapillaris and Retinal Vascular Flow Changes on OCTA with Progression to Advanced AMD.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease.Medicina (Kaunas, Lithuania) · 2024Review
- The Potential Causal Association of Apolipoprotein A and B and Age-Related Macular Degeneration: A Mendelian Randomisation Study.Biomedicines · 2024Article
- Associations of mediterranean diet score and age-related macular degeneration in Korean elderly.BMC public health · 2024Article
- Differential gene expression between central and peripheral retinal regions in dogs and comparison with humans.Experimental eye research · 2024Article
- Analysis of macular thickness and peripapillary retinal nerve fiber layer thickness in various ABO and Rh blood groups.BMC ophthalmology · 2024Article
28 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
Age-related macular degeneration (AMD) is a progressive blinding disease and represents the leading cause of visual impairment in the aging population. AMD affects central vision which impairs one's ability to drive, read and recognize faces. There is no cure for this disease and current treatment modalities for the exudative form of the disease require repeated intravitreal injections which may be painful, are incompletely efficacious, and represent a significant treatment burden for both the patient and physician. As such, AMD represents a significant and important clinical problem.It is anticipated that in three years' time, 196 million individuals will be affected with AMD. Over 250 billion dollars per year are spent on care for AMD patients in the US. Over half of the heritability is explained by two major loci, thus AMD is considered the most well genetically defined of the complex disorders. A recent GWAS on 43,566 subjects identified novel loci and pathways associated with AMD risk, which has provided an excellent platform for additional functional studies. Genetic variants have been investigated, particularly with respect to anti-VEGF treatment, however to date, no pharmacogenomic associations have been consistently identified across these studies. It may be that if the goal of personalized medicine is to be realized and biomarkers are to have predictive value for determining the magnitude of risk for AMD at the genetic level, one will need to examine the relationships between these pathways across disease state and relative to modifiable risk factors such as hypertension, smoking, body mass index, and hypercholesterolemia. Further studies investigating protective alleles in populations with low AMD prevalence may lead to this goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.